Chronic L-dopa Decreases Serotonin Neurons in a Subregion of the Dorsal Raphe Nucleus

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2014 Sep 13

PMID 25212217

Citations 15

Authors

Branden J Stansley

Bryan K Yamamoto

Affiliations

Soon will be listed here.

Abstract

L-Dopa (l-3,4-dihydroxyphenylalanine) is the precursor to dopamine and has become the mainstay therapeutic treatment for Parkinson's disease. Chronic L-dopa is administered to recover motor function in Parkinson's disease patients. However, drug efficacy decreases over time, and debilitating side effects occur, such as dyskinesia and mood disturbances. The therapeutic effect and some of the side effects of L-dopa have been credited to its effect on serotonin (5-HT) neurons. Given these findings, it was hypothesized that chronic L-dopa treatment decreases 5-HT neurons in the dorsal raphe nucleus (DRN) and the content of 5-HT in forebrain regions in a manner that is mediated by oxidative stress. Rats were treated chronically with l-dopa (6 mg/kg; twice daily) for 10 days. Results indicated that the number of 5-HT neurons was significantly decreased in the DRN after l-dopa treatment compared with vehicle. This effect was more pronounced in the caudal-extent of the dorsal DRN, a subregion found to have a significantly higher increase in the 3,4-dihydroxyphenylacetic acid/dopamine ratio in response to acute L-dopa treatment. Furthermore, pretreatment with ascorbic acid (400 mg/kg) or deprenyl (2 mg/kg) prevented the l-dopa-induced decreases in 5-HT neurons. In addition, 5-HT content was decreased significantly in the DRN and prefrontal cortex by l-dopa treatment, effects that were prevented by ascorbic acid pretreatment. Taken together, these data illustrate that chronic L-dopa causes a 5-HT neuron loss and the depletion of 5-HT content in a subregion of the DRN as well as in the frontal cortex through an oxidative-stress mechanism.

Citing Articles

Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.

Conti Mazza M, Centner A, Werner D, Bishop C Brain Res. 2023; 1811:148381.

PMID: 37127174 PMC: 10562932. DOI: 10.1016/j.brainres.2023.148381.

Oxidative Stress and Cognitive Decline: The Neuroprotective Role of Natural Antioxidants.

Franzoni F, Scarfo G, Guidotti S, Fusi J, Asomov M, Pruneti C Front Neurosci. 2021; 15:729757.

PMID: 34720860 PMC: 8548611. DOI: 10.3389/fnins.2021.729757.

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia-Literature Review.

Hutny M, Hofman J, Klimkowicz-Mrowiec A, Gorzkowska A J Clin Med. 2021; 10(19).

PMID: 34640395 PMC: 8509231. DOI: 10.3390/jcm10194377.

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID).

Yang K, Zhao X, Wang C, Zeng C, Luo Y, Sun T Front Neurosci. 2021; 15:614412.

PMID: 33776634 PMC: 7988225. DOI: 10.3389/fnins.2021.614412.

The effect of 5-HT receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats.

Vegas-Suarez S, Aristieta A, Requejo C, Bengoetxea H, Lafuente J, Miguelez C Br J Pharmacol. 2021; 178(12):2516-2532.

PMID: 33686657 PMC: 8252460. DOI: 10.1111/bph.15437.

References

Forster G, Feng N, Watt M, Korzan W, Mouw N, Summers C . Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience. 2006; 141(2):1047-1055. DOI: 10.1016/j.neuroscience.2006.04.006. View

Agus D, Gambhir S, Pardridge W, Spielholz C, Baselga J, Vera J . Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1998; 100(11):2842-8. PMC: 508490. DOI: 10.1172/JCI119832. View

Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D . Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci. 2007; 27(30):8011-22. PMC: 6672736. DOI: 10.1523/JNEUROSCI.2079-07.2007. View

Ishida Y, Hashiguchi H, Todaka K, Ishizuka Y, Mitsuyama Y . Repeated administration of high dose levodopa enhances hydroxyl radical production in the rat striatum denervated with 6-hydroxydopamine. Neurosci Lett. 2000; 290(1):33-6. DOI: 10.1016/s0304-3940(00)01320-3. View

Camp D, Loeffler D, Lewitt P . L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem. 2000; 74(3):1229-40. DOI: 10.1046/j.1471-4159.2000.741229.x. View

Albert P, Vahid-Ansari F, Luckhart C . Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci. 2014; 8:199. PMC: 4047678. DOI: 10.3389/fnbeh.2014.00199. View

Engeln M, De Deurwaerdere P, Li Q, Bezard E, Fernagut P . Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cereb Cortex. 2014; 25(9):2783-92. DOI: 10.1093/cercor/bhu076. View

Warden M, Selimbeyoglu A, Mirzabekov J, Lo M, Thompson K, Kim S . A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature. 2012; 492(7429):428-32. PMC: 5929119. DOI: 10.1038/nature11617. View

Juorio A, Li X, Walz W, Paterson I . Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res. 1993; 626(1-2):306-9. DOI: 10.1016/0006-8993(93)90592-b. View

10.

Spina M, Cohen G . Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A. 1989; 86(4):1398-400. PMC: 286698. DOI: 10.1073/pnas.86.4.1398. View

11.

Graham D . Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978; 14(4):633-43. View

12.

Fernandez H, Chen J . Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy. 2007; 27(12 Pt 2):174S-185S. DOI: 10.1592/phco.27.12part2.174S. View

13.

Mena M, Pardo B, Casarejos M, Fahn S, Garcia de Yebenes J . Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord. 1992; 7(1):23-31. DOI: 10.1002/mds.870070105. View

14.

Navailles S, Bioulac B, Gross C, De Deurwaerdere P . Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis. 2010; 38(1):136-43. DOI: 10.1016/j.nbd.2010.01.012. View

15.

Amat J, Baratta M, Paul E, Bland S, Watkins L, Maier S . Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci. 2005; 8(3):365-71. DOI: 10.1038/nn1399. View

16.

Hauser R . Levodopa: past, present, and future. Eur Neurol. 2009; 62(1):1-8. DOI: 10.1159/000215875. View

17.

Carta M, Carlsson T, Kirik D, Bjorklund A . Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007; 130(Pt 7):1819-33. DOI: 10.1093/brain/awm082. View

18.

Riederer P, Laux G . MAO-inhibitors in Parkinson's Disease. Exp Neurobiol. 2011; 20(1):1-17. PMC: 3213739. DOI: 10.5607/en.2011.20.1.1. View

19.

Eskow Jaunarajs K, Angoa-Perez M, Kuhn D, Bishop C . Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev. 2010; 35(3):556-64. PMC: 2987522. DOI: 10.1016/j.neubiorev.2010.06.007. View

20.

Hashimoto S, Inoue T, Koyama T . Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur J Pharmacol. 1999; 378(1):23-30. DOI: 10.1016/s0014-2999(99)00441-0. View